Interview with Igor Kouznetsov, General Director, Euroservice
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
Address: 47, bld. 4, office 8B, Varshavskoe shosse, Moscow, 115230,Russia
Tel: +7 (499) 272 0500
Web: http://www.imshealth.com/portal/site/ims
IMS first opened offices in Russia in 1993, and we have a large team to support your business development.
The demand for reliable market intelligence and accountability in global healthcare has never been greater. From researchers and payers to government agencies and pharmaceutical manufacturers, healthcare stakeholders need to better understand the role prescription drugs play in delivering high-quality, cost-effective care. At the same time, pharmaceutical companies face unprecedented competition for market share and pressures to maximize brand lifecycles, all while proving the value of their medicines.
In today’s complex healthcare marketplace, a growing set of audiences depend on IMS to yield the most accurate perspective of global market dynamics.
Organizing a vast array of healthcare data and facts into solid, relevant metrics to help answer key questions is an enormous undertaking. IMS can apply insight and capabilities to a tremendously rich set of data assets and analytics. We are the gold standard in pharmaceutical and healthcare market intelligence, relied on by virtually all of the world’s largest pharmaceutical and biotech companies — along with government agencies, policymakers, researchers and financial analysts around the globe.
Our end-to-end solutions — integrating unparalleled information, analytics, consulting and services — play a central role in supporting high-quality, cost-effective healthcare. Our people bring the facts and figures to life, leveraging our extensive global network and expertise.
To help clients succeed in the Russian healthcare marketplace, IMS provides a number of specialized offerings:
National and Sub-National:
Retail Audits
Hospital Audits
Reimbursement Audits
Consulting Capabilities
Promotional Tracking in Four Therapy Areas
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have…
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
See our Cookie Privacy Policy Here
